Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
about
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibAcalabrutinib (ACP-196): a selective second-generation BTK inhibitorThe splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLBTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In VivoTreatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignanciesDisruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyGIFT4 fusokine converts leukemic B cells into immune helper cellsChronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient processPreclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the tradeChronic lymphocytic leukemia therapy: new targeted therapies on the wayFBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib.Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphomaTargeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.Shifting paradigms in the treatment of chronic lymphocytic leukemia.The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.Overview of the Use of Murine Models in Leukemia and Lymphoma Research.Whole exome sequencing in families with CLL detects a variant in Integrin β 2 associated with disease susceptibility.Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
P2860
Q27025812-916E8F89-0F06-4FDC-9C05-1DC87DA0F432Q28066316-A12A9DDC-70A5-49DB-9D3D-58CB70328709Q30395427-4942ADD3-EC05-412F-B713-BC81116A8D4CQ33714712-0E5427A5-C81F-41B1-909A-6D314737F6DBQ34041311-DE1D0251-B417-425E-94D9-D2C934EE3CB6Q34289493-2A6D4C5E-5EF1-44A2-B102-3D2DCF759B66Q34718363-30BCE9E5-2E6E-4EEF-AAB3-0A92C43B70E7Q36025695-4A48AD14-BEB0-478D-80AF-74ECFEB08A37Q36172601-57639995-4B1E-41E1-B2D3-BA7AC34D3BC0Q36245171-32855294-1AA8-4866-A5DB-1DEBBA81DF58Q36334833-C91F9EB2-383D-44B2-9934-5218BC8596B8Q36759124-A3F66FF4-289D-4413-B045-DD6DE390F22BQ36842259-064F0643-B515-493E-845D-8D8BE96254D9Q36867167-9F37ABF5-7520-40FF-9110-3AB505206DB4Q36867755-9AE535FC-B54C-49B6-AF37-4BDFAA2C5FCCQ37113544-0E0FB0E0-48E9-4C48-A1F7-04F4BD4C6352Q37404843-B3654D3B-E8CF-4AAB-8A8D-4F57A0B1D86CQ37599562-770099A8-BCAB-494F-8E69-3EAABA429D9EQ37688589-81A71958-C1E1-4821-A53D-DC32494800B0Q37706530-06AE4DB2-D171-4D94-AD94-1E5EB41299E3Q37731677-4A1D919C-4AA3-443F-B594-2CA9B770E933Q38351184-15F86F2A-3C15-4776-BB0F-0865BCCA664CQ38357127-B079C8C0-4F31-4D54-A1B3-CC539AED7649Q38745915-D243C4A7-1A8A-4ABD-831F-F573AABF38C2Q38749909-00A0B8BC-6E84-4407-ABAE-73CB5017FE29Q42733617-923504C7-821E-4792-B55E-4E7B98B860D9Q46074725-0D5BFAF1-57D9-4EA9-BAA7-22EFA9B7FE64Q46566477-26D4FCE8-4C12-4EF4-BECC-B8C709FA84D7Q49818504-7918AC18-9083-437A-B64C-A8D8BAC96768Q53963822-01FFCF5F-F04F-4C62-89F8-E3F58F6A5173Q54979456-79C48844-8A20-4FCE-9D0A-FE85EF8C5123Q55280895-B7A7CF50-DC40-4250-A72B-F02C2C11E162
P2860
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Modeling tumor-host interactio ...... and evaluate targeted therapy
@ast
Modeling tumor-host interactio ...... and evaluate targeted therapy
@en
Modeling tumor-host interactio ...... and evaluate targeted therapy
@nl
type
label
Modeling tumor-host interactio ...... and evaluate targeted therapy
@ast
Modeling tumor-host interactio ...... and evaluate targeted therapy
@en
Modeling tumor-host interactio ...... and evaluate targeted therapy
@nl
prefLabel
Modeling tumor-host interactio ...... and evaluate targeted therapy
@ast
Modeling tumor-host interactio ...... and evaluate targeted therapy
@en
Modeling tumor-host interactio ...... and evaluate targeted therapy
@nl
P2093
P2860
P921
P356
P1433
P1476
Modeling tumor-host interactio ...... and evaluate targeted therapy
@en
P2093
A Wiestner
C M Chapman
E M McAuley
J F Tisdale
K Keyvanfar
P2860
P2888
P304
P356
10.1038/LEU.2013.131
P577
2013-04-26T00:00:00Z
P5875
P6179
1039143528